Sign in
Taking people in South KoreaPhase 4

Lowering or stopping febuxostat in people whose gout is well controlled

Tests a smaller febuxostat dose or a pause in people with well-controlled gout.

Key facts

Who runs it
Seoul National University Hospital
Where
Seongnam-si, South KoreaSee the site
Trial code
Registry title
the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
Status
Recruiting
Phase
Phase 4
People taking part
59 people, planned
Started
10 Sept 2025
Expected to end
19 Aug 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Febuxostat
Record updated
29 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with gout whose uric acid has been well controlled on uric-acid-lowering medicine for at least 5 years. It tests lowering or pausing febuxostat.

Age
19 to 79 years (at least 19 and under 80).
Sex
All sexes.
Disease stage
Gout well controlled for at least the past 5 years. No lumps of uric acid crystals (tophi) seen or felt. No gout attack or kidney stones in the past 12 months.
Earlier treatment
Must have taken allopurinol, febuxostat, or both for at least the past 5 years. Cannot join if already on a low dose (allopurinol ≤200 mg/day or febuxostat ≤20 mg/day) of one drug alone; low doses of both combined are allowed.
Biomarker or test result
At least five blood uric acid tests in the past 5 years, all below 6.0 mg/dL, or an overall 5-year uric acid level (AUC) under 33.0 mg/dL x year. Kidney function (eGFR) of 60 mL/min/1.73m² or higher.

Main reasons for not taking part

  • Needing ongoing low-dose colchicine or NSAIDs to prevent attacks.
  • Taking medicines that change uric acid levels, such as benzbromarone, fenofibrate, loop or thiazide diuretics, or losartan, or taking mercaptopurine or azathioprine.
  • Heavy drinking: men under 65 more than 14 drinks a week; men 65 or older and women more than 7.
  • Allergy to febuxostat or allopurinol.
  • Unstable heart or blood vessel disease, or moderate or severe liver problems (AST or ALT more than 3 times the upper normal limit).

The registry criteria, word for word

Show all 2 criteriaShow less

Other criteria

  • Inclusion Criteria:; Adult gout patients aged ≥19 but <80 years; Gout patients treated with urate-lowering therapy (either allopurinol or febuxostat monotherapy, or a combination of two agents) for at least the past 5 years; Patients who have at least five serum urate level measurements over the past 5 years and meet one of the following criteria:; All serum urate levels measured in the past 5 years have been maintained below 6.0 mg/dL; or the area under the curve (AUC) of serum urate levels over time for the past 5 years is less than 33.0 mg/dL x year; Patients without palpable or visible tophi on physical examination (evaluated at pre-defined 18 joint sites and the ears); Patients without acute gouty attack or history of nephrolithiasis in the past 12 months; Patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73m² or higher, based on the Cockcroft-Gault formula; Patients who voluntarily provide written informed consent to participate
  • Exclusion Criteria:; Subjects who continuously require prophylactic low-dose colchicine/NSAIDs; Subjects already having taken low-dose urate-lowering agents. The low-dose urate-lowering agents are defined as allopurinol ≤200 mg/day or febuxostat ≤20 mg/day. But patients on a combination of low-dose allopurinol and febuxostat are eligible; Subjects taking medications that could affect serum uric acid levels and uric acid fractional excretion rates, such as benzbromarone, fenofibrate, loop diuretics, thiazide or thiazide-like diuretics, and losartan; Subjects classified as having high-risk alcohol use according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA):; For men <65 years: more than 14 drinks per week or for men ≥65 years or women: more than 7 drinks per week; Subjects with a history of hypersensitivity to febuxostat or allopurinol; Subjects with unstable cardiovascular conditions, who require adjustment of urgent their therapy; Subjects taking mercaptopurine or azathioprine; Subjects with genetic issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; Subjects with moderate or severe liver dysfunction (AST or ALT levels greater than 3 times the upper normal limit); Subjects for whom investigators anticipate that a change in a urate-lowering agent dose could present significant risks or that any factor could severely impact drug adherence, complicating study registration

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 19 and 79 years old?

Where in South Korea

  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Yun Jong Lee, M.D, PhDTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to compare the changes in serum urate levels and symptom recurrence after reducing or suspending urate-lowering agents in well-controlled gout patients (the 'after dishes are clean' state in the Dirty Dish hypothesis)

Read full original descriptionShow less

Researchers will compare three randomized groups: the reducing group takes febuxostat 20 mg once daily for 12 months, the discontinuing group takes a placebo once daily for 6 months, followed by febuxostat 20 mg once daily for the next 6 months, and the maintaining group continues their pre-study urate-lowering agents for 12 months, serving as an observational reference group.

During the 12-month study period, participants will visit every 3 months for laboratory evaluations including serum urate levels, and for checking symptomatic status using questionnaires and diaries. Additionally, musculoskeletal ultrasonography and serum sample collection will be performed at baseline to study predictors for maintaining serum urate levels <7.0 mg/dL after reducing or suspending urate-lowering therapy.

The 3 groups in the trial

  • Discontinuing groupPlacebo, for comparison

    The participants (n=15) will take a placebo once daily for 6 months, followed by febuxostat 20 mg once daily for the next 6 months. Randomization is stratified based on the urinary urate excretion rate (≤5.5% vs. \>5.5%).

    Treatment: Febuxostat

  • Reducing groupExisting treatment, for comparison

    The participants (n=29) will take febuxostat 20 mg once daily for 12 months. Randomization is stratified based on the urinary urate excretion rate (≤5.5% vs. \>5.5%).

    Treatment: Febuxostat

  • Maintaining groupNo study treatment, for comparison

    To serve as an observational reference group, The participants (n=15) will continue their urate-lowering agents for 12 months. Randomization is stratified based on the urinary urate excretion rate (≤5.5% vs. \>5.5%).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Randomized Investigator Initiative Clinical Trial Study on the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
Plain-language title
Lowering or stopping febuxostat in people whose gout is well controlledGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06622603, who can take part
Record updated
29 April 2026